IL6 and myocardial infarction: IL-6 inhibitor: Tocilizumab, an IL-6 antagonist, has emerged as a promising agent for reducing the inflammatory burden encountered during acute MI since IL-6 is a pro-inflammatory cytokine implicated in endothelial injury, inflammatory cell recruitment, and microthrombi formation.